Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging ...Middle East

PR Newswire - News
Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging
MELBOURNE, Australia, Oct. 16, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved an investigational new drug (IND) application to...

Hence then, the article about chinese nmpa approves pivotal phase iii study of tlx591 cdx for prostate cancer imaging was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News